About Us

Dr. Feng Yu has nearly two decades of experience in biomedical innovation. Before founding ELI Radiopharma, he served as General Manager and Senior VP of R&D at Suzhou BoomRay, overseeing early development, translational research, registration, and patent strategy, and led the company through a nearly RMB 300 million Series A financing. Prior to that, he was the domestic person-in-charge at APRINOIA Therapeutics, advancing China’s first innovative diagnostic radiopharmaceutical project to Phase III clinical trials. Over his career, Dr. Yu has contributed to the R&D, translation, and clinical application of multiple innovative radiopharmaceuticals. He began his career at GlaxoSmithKline’s R&D Center, conducted basic research at the Shanghai Biochemical Cell Institute (Chinese Academy of Sciences), and holds a master’s degree from Fudan University and a Ph.D. from Shanghai University of Traditional Chinese Medicine.